Pharmaceutical Investing Ritter Pharmaceuticals Completes Dosing of Last Patient in Pivotal 557-Subject Phase 3 Clinical Trial
AMENDED FROM SOURCE - Blue Sky Uranium Increases and Closes 2nd and Final Tranche of the Oversubscribed Non-Brokered Private Placement
